Skip to main content
Amandeep Salhotra, MD, Oncology, Duarte, CA

AmandeepSalhotraMD

Oncology Duarte, CA

Associate Professor, Department of Hematology, Hematopoietic Cell Transplantation

Dr. Salhotra is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Salhotra's full profile

Already have an account?

  • Office

    1500 Duarte Rd
    Duarte, CA 91010
    Phone+1 626-256-4673
    Fax+1 626-930-5446

Summary

  • Dr. Amandeep Salhotra is an oncologist in Duarte, CA and is affiliated with City of Hope's Helford Clinical Research Hospital. He received his medical degree from Maulana Azad Medical College and has been in practice 18 years. He specializes in hematologic oncology and is experienced in amyloidosis, hematologic oncology, myelodysplasia, myelofibrosis, and multiple myeloma.

Education & Training

  • University of Virginia Medical Center
    University of Virginia Medical CenterFellowship, Hematology and Medical Oncology, 2010 - 2012
  • St Elizabeth's Medical Center
    St Elizabeth's Medical CenterFellowship, Hematology and Medical Oncology, 2009 - 2010
  • St Elizabeth's Medical Center
    St Elizabeth's Medical CenterResidency, Internal Medicine, 2006 - 2009
  • Maulana Azad Medical College
    Maulana Azad Medical CollegeClass of 1999

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 2012 - 2026
  • VA State Medical License
    VA State Medical License 2010 - 2012
  • MA State Medical License
    MA State Medical License 2009 - 2011

Clinical Trials

Publications & Presentations

PubMed

Abstracts/Posters

  • Optimization of Tacrolimus Serum Levels When Combined with Post-Transplant Cyclophosphamide As Graft-Versus-Host Disease Prophylaxis after Hematopoietic Cell Transplan...
    Amandeep Salhotra, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Peri-Transplant Administration of Ruxolitinib Is Safe and Feasible in Patients with Myelofibrosis: Primary Results of a Pilot Open-Label Study of Ruxolitinib Administr...
    Amandeep Salhotra, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • KD025 for Patients with Chronic Graft-Versus-Host Disease (cGVHD) _ Long-Term Follow-up of a Phase 2a Study (KD025-208)
    Amandeep Salhotra, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

  • Long Term Outcomes of Patients with Aggressive T-Cell Non-Hodgkin Lymphoma Undergoing Allogeneic Stem Cell Transplantation: Retrospective Results from a Single Center 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
  • MIPSS70+ V2.0 and Revised Cytogenetics Changes Predict Outcomes of Allogeneic Transplantation with Fludarabine and Melphalan Conditioning in Patients with Myelofibrosis 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Clinical Outcomes of MDS Patients Who Were Allogeneic Hematopoietic Stem Cell Transplant Candidates but Did Not Proceed with Transplantation 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Authored Content

  • Optimizing Outcomes with Myeloablative Conditioning in Older Patients: Efficacy and Safety of Precision Engineered Orca-T in Patients > 55 Years Old with Hematologic MalignanciesDecember 2023

Press Mentions

  • Plerixafor Doesn’t Overcome HPC Failure in R-hyperCVAD for Mantle Cell Lymphoma
    Plerixafor Doesn’t Overcome HPC Failure in R-hyperCVAD for Mantle Cell LymphomaSeptember 10th, 2017